Insulin Dose Not Tied to Cardiovascular Outcomes

This article originally appeared here.
Share this content:
Insulin Dose Not Tied to Cardiovascular Outcomes
Insulin Dose Not Tied to Cardiovascular Outcomes

MONDAY, Sept. 25, 2017 (HealthDay News) -- Cardiovascular outcomes in patients with diabetes are not explained by insulin resistance, according to research published online Sept. 12 in Diabetes, Obesity and Metabolism.

Hertzel C. Gerstein, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted secondary analyses of participants allocated to insulin glargine, who added it to lifestyle or one glucose lowering oral agent at randomization. Calculations included the median of the natural logarithm of the insulin doses (expressed per kilogram of fat-free mass) from every visit from randomization until either the penultimate visit or the first occurrence of a cardiovascular outcome.

The researchers found that higher median insulin doses did not reflect incident cardiovascular events overall or in the subset that achieved normoglycemia. The adjusted hazard of the composite of cardiovascular death, myocardial infarction, or stroke was 0.94 (95 percent confidence interval, 0.88 to 1.00) per unit higher dose overall, and 0.91 (95 percent confidence interval, 0.81 to 1.01) in the normoglycemic subset, when examining the dose taken before a cardiovascular event or the penultimate visit.

"Insulin resistance may not promote cardiovascular outcomes in people with dysglycemia," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »